(Q38384533)

2 September 2017

1 reference

title

The history of vaccination against cytomegalovirus (English)

1 reference

2 September 2017

1

Stanley Plotkin

1 reference

2 September 2017

publication date

20 March 2015

1 reference

Medical Microbiology and Immunology

2 September 2017

published in

1 reference

2 September 2017

volume

204

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

247-254

1 reference

The history of cytomegalovirus and its diseases

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Cytomegalovirus infection in critically ill patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Cytomegalovirus infection: a driving force in human T cell immunosenescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Clinical Trials of Immunization with the Towne 125 Strain of Human Cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Immunisation trials with live attenuated cytomegalovirus TOWNE 125

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Safety and immunogenicity of the Towne strain cytomegalovirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

A review of genetic differences between limited and extensively passaged human cytomegalovirus strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Cytomegalovirus vaccine virus (Towne strain) does not induce latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Resistance of seropositive volunteers to subcutaneous challenge with low-passage human cytomegalovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Vaccine prevention of maternal cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Cytomegalovirus pp65 limits dissemination but is dispensable for persistence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Nonviral delivery of self-amplifying RNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Universal neonatal cytomegalovirus screening using saliva - report of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0388-Z

Vaccination of pediatric nurses with live attenuated cytomegalovirus

21 January 2018

1 reference

12 December 2020

T-lymphocyte subsets and proliferative responses following immunization with cytomegalovirus vaccine

1 reference

12 December 2020

Cytomegalovirus vaccine prepared in WI-38

1 reference

12 December 2020

Immune responses to isolated human cytomegalovirus envelope proteins

1 reference

12 December 2020

Detection of Antibody to Cytomegalovirus Early Antigen in Vaccinated, Normal Volunteers and Renal Transplant Candidates

1 reference

12 December 2020

Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine

1 reference

12 December 2020

Clinical and Laboratory Studies of Live Cytomegalovirus Vaccine Ad-169

1 reference

12 December 2020

Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs

1 reference

12 December 2020

Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response

1 reference

12 December 2020

Detection of antibodies to pre-early nuclear antigen and immediate-early antigens in patients immunized with cytomegalovirus vaccine

1 reference

12 December 2020

Candidate cytomegalovirus strain for human vaccination

1 reference

12 December 2020

Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection.

1 reference

12 December 2020

Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome

1 reference

12 December 2020

Cytomegalovirus in hematopoietic stem cell transplant recipients

1 reference

12 December 2020

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

1 reference

12 December 2020

Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis

1 reference

12 December 2020

Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains.

1 reference

12 December 2020

Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients.

1 reference

12 December 2020

A recombinant subunit vaccine approach to HCMV vaccine development

1 reference

12 December 2020

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

12 December 2020

10.1007/S00430-015-0388-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1043061212

0 references

1 reference